Clinical Trial

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Study acronym: TERZO
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2024-07-22; most recent amendment 2026-04-03.
Status change: Not Yet Recruiting → Recruiting 2025-04-22
Trial Details
NCT Number NCT06522737
Lead Sponsor SecuraBio
Conditions Lymphoma
Enrollment 124 participants
Start Date 2025-05-19
Primary Completion 2028-02 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-06